22
Participants
Start Date
December 13, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
SI-B001
Administered by intravenous drip every 2 weeks (Q2W). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.
Irinotecan
The dose of irinotecan was 180mg/m2 Q2W, the infusion method was according to the drug instructions, SI-B001 and irinotecan were used on the same day, and irinotecan was injected after SI-B001 infusion.
Beijing Cancer Hostital, Beijing
Anyang Cancer Hospital of Henan Province, Anyang
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
Xuzhou Central Hospital, Xuzhou
Shanxi Cancer Hospital, Taiyuan
Suining Central Hospital, Suining
Sichuan Baili Pharmaceutical Co., Ltd.
INDUSTRY